Vemurafenib (PLX4032, RG7204)
(Synonyms: 维罗非尼; PLX4032; RG7204; RO5185426) 目录号 : GC13412
Vemurafenib (PLX4032, RG7204)是一种选择性的强效B-RAF抑制剂，对BRAFV600E和c-RAF-1的IC50分别为31和48nM。
Cas No.:918504-65-1
Sample solution is provided at 25 µL, 10mM.
Vemurafenib (PLX4032, RG7204) is a selective and potent inhibitor of B-RAF with IC50 values of 31 and 48nM for BRAFV600E and c-RAF-1, respectively [1]. Protein kinase B-RAF is a key component of the RAS-RAF signaling pathway, which plays a significant role in regulating cell proliferation, differentiation, and survival [2]. Vemurafenib can be used to induce autophagy and inhibit tumor growth [3-4].
In vitro, Vemurafenib (0.05-30μM; 2h) treatment significantly inhibited the phosphorylation of MEK and ERK in the melanoma cell lines Colo829 and LOX that express BRAFV600E. The inhibition of ERK and MEK phosphorylation by Vemurafenib is related to its inhibition of the growth of melanoma cells with V600 site mutations [5]. Vemurafenib (1μM; 24h) treatment significantly inhibited the growth, migration, and invasion of PC3 cells overexpressing Palm-PTK6-YF [6].
In vivo, Vemurafenib (12.5, 25, and 75mg/kg; 13d; p.o.) dose-dependently inhibited tumor growth in mice carrying LOX xenografts and induces tumor regression [5]. Vemurafenib (10mg/kg/day; 16d; i.p.) treatment had an inhibitory effect on tumor growth in C57BL/6 mice with subcutaneous inoculated SM1 tumors [7].
References:
[1] Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.
[2] Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer[J]. Cancer research, 2012, 72(3): 779-789.
[3] Wang W, et al. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.J Clin Endocrinol Metab. 2017 Feb 1;102(2):634-643.
[4] Lee W R, Shen S C, Shih Y H, et al. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts[J]. Journal of Translational Medicine, 2015, 13(1): 191.
[5] Yang H, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010, 70(13), 5518-5527.
[6] Wozniak D J, Hitchinson B, Gilic M B, et al. Vemurafenib inhibits active PTK6 in PTEN-null prostate tumor cells[J]. Molecular cancer therapeutics, 2019, 18(5): 937-946.
[7] Koya R C, Mok S, Otte N, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy[J]. Cancer research, 2012, 72(16): 3928-3937.
Vemurafenib (PLX4032, RG7204)是一种选择性的强效B-RAF抑制剂，对BRAFV600E和c-RAF-1的IC50分别为31和48nM[1]。蛋白激酶B-RAF是RAS-RAF信号通路的关键组成部分，该通路在调控细胞增殖、分化和存活方面发挥着重要作用 [2]。Vemurafenib可用于诱导细胞自噬和抑制肿瘤生长[3-4]。
在体外，Vemurafenib（0.05-30μM; 2h）处理显著抑制了表达BRAFV600E的黑色素瘤细胞系Colo829和LOX中MEK和ERK的磷酸化。Vemurafenib对ERK和MEK磷酸化的抑制与其对V600位点突变的黑色素瘤细胞细胞生长的抑制相关[5]。Vemurafenib（1μM; 24h）处理显著抑制了Palm-PTK6-YF过表达的PC3细胞的生长、迁移和侵袭 [6]。
在体内，Vemurafenib（12.5、25和75mg/kg; 13d; p.o.）剂量依赖性地抑制了携带LOX异种移植瘤的小鼠的肿瘤生长，并诱导肿瘤消退[5]。Vemurafenib（10mg/kg/day; 16d; i.p.）治疗对皮下接种SM1肿瘤的C57BL/6小鼠的肿瘤生长具有抑制作用 [7]。
| Cell experiment [1]: | |
Cell lines | PC3 Vector and PC Palm-PTK6-YF |
Preparation Method | For proliferation assays, 1 × 105 cells were seeded in triplicate into six-well plates on day 0. Two cell lines, PC3 Vector and PC Palm-PTK6-YF were treated with either DMSO or 1μM Vemurafenib. Drug and vehicle were added to the cells on day 1. Each following day, cells in three wells were trypsinized and resuspended in culture media and quantified. |
Reaction Conditions | 1μM; 24, 48h |
Applications | Vemurafenib significantly inhibited the growth, migration and invasion of PC3 cells with overexpressed Palm-PTK6-YF. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | The SM1 murine melanoma was generated from a spontaneously arising tumor in BRAFV600E mutant transgenic mice. The tumor was minced and first implanted into mice, and then serially implanted into C57BL/6 mice for in vivo experiments. Vemurafenib was dissolved in dimethylsulfoxide (DMSO) and used as previously described. SM1 tumor implanted mice were injected i.p. daily with 10mg/kg of Vemurafenib or vehicle control and followed for tumor-size changes over time. |
Dosage form | 10mg/kg/day; Single-dose; p.o. |
Applications | Vemurafenib exhibits growth inhibitory effects on SM1 tumors implanted subcutaneously in C57BL/6 mice. |
References: | |
| Cas No. | 918504-65-1 | SDF | |
| 别名 | 维罗非尼; PLX4032; RG7204; RO5185426 | ||
| 化学名 | N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide | ||
| Canonical SMILES | CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F | ||
| 分子式 | C23H18ClF2N3O3S | 分子量 | 489.93 |
| 溶解度 | ≥ 24.5mg/mL in DMSO | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0411 mL | 10.2055 mL | 20.4111 mL |
| 5 mM | 0.4082 mL | 2.0411 mL | 4.0822 mL |
| 10 mM | 0.2041 mL | 1.0206 mL | 2.0411 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet